Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

WIN 2012 /
Introduction of PET tracers to the WINTHER trial

28th - 29th Jun 2012

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.07.12
Views: 2976

Robert Dann - Global Strategy Leader, Oncology/Pathology, GE Healthcare

Robert Dann discusses a collaboration between the WIN consortium and GE Healthcare which will allow the use of PET angiogenesis tracers within the WINTHER study.

It is hoped that the use of this imagine technique will allow clinicians to identify patients who are not responding to the WINTHER therapy at an early stage and if so, to discontinue treatment.

Dr Dann explains how this move will benefit both the patients taking part in the study and will also contribute to the validation of the tracer, speeding its progression into clinical application.

Although GE Healthcare has traditionally concentrated solely on imaging development, this partnership is part of an attempt to broaden the services offered and it is hoped this will pave the way for further collaborations between academia and pharmaceutical companies.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation